Fig. 3

Differences between screening subpopulations within clinical subgroups/PAM50 molecular subtypes found through gene expression data. a Distribution of a tumor proliferation measure calculated in silico per sample by screening status of patients and by relevant clinical subgroups or PAM50 molecular subtypes. b Fold change distribution and number of differentially expressed genes in screened patients when compared to non-screened patients. c, d Enrichment scores of two immune cell types by screening status and by age at diagnosis (in years) within all TNBC cases. R = Spearman’s correlation coefficient